At Merck, we are passionate about improving health and are committed to helping people with cancer, so we established Keynote — a series of clinical trials to determine whether the investigational immunotherapy pembrolizumab (MK-3475) may help in the treatment of cancer. We have clinical trials planned in multiple cancer types (see below).
The FDA has approved Pembrolizumab for use in patients with advanced melanoma, non-small cell lung cancer and recurrent or metastatic head and neck squamous cell carcinoma.
There is a great deal more to learn to better understand which patients are likely to respond to immunotherapy. Ongoing research activities may help us understand this as well as provide insight regarding how best to test for expression of biomarkers that may better direct clinical care.
Merck is currently evaluating pembrolizumab for multiple types of cancer alone and in combination with other therapies. Future clinical trials may be planned and/or conducted in additional cancers. The cancer types listed below currently have active trial listings on ClinicalTrials.gov. Click on a protocol number to be directed to that trial's information.